Robert Dagil
Director, Bispecific Antibodies & CMC VAR2 Pharmaceuticals
Robert Dagil has a PhD degree in the field of structural biology and protein science and joined VAR2 Pharmaceuticals in 2017. Robert is leading the bispecific protein production team and brings technical and scientific expertise within protein engineering and CMC process development.
Seminars
Wednesday 13th January 2027
Advancing Rationally Designed Antibody Leads into Development Candidates Through Structural Validation & Translational Characterisation
12:30 pm
- Leverage phage display, structural biology and Cryo-EM to identify, characterise and down-select antibody leads against novel pan-cancer target onco-fetal chondroitin sulfate
- Integrate target biology, binding characterisation and in vivo localisation studies to prioritise candidates with the greatest translational potential
- Optimise pharmacokinetic profile using structural biology and functional datasets to de-risk candidate selection and increase confidence in progression toward clinical development
